ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer
Science Advances · 07.04.2023 · 9 (14)
DOI: 10.1126/sciadv.adc9446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 07.04.2023. Verfasst von Dan Li und 19 weiteren Autor:innen. Beteiligte Einrichtung: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Intraepithelial Neoplasia. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The mechanisms underlying ETS -driven prostate cancer initiation and progression remain poorly understood due to a lack of model systems that recapitulate this phenotype. We generated a genetically engineered mouse with prostate-specific expression of the ETS factor, ETV4, at lower and higher protein dosage through mutation of its degron. Lower-level expression of ETV4 caused mild luminal cell expansion without histologic abnormalities, and higher-level expression of stabilized ETV4 caused prostatic intraepithelial neoplasia (mPIN) with 100% penetrance within 1 week. Tumor progression was limited by p53-mediated senescence and Trp53 deletion cooperated with stabilized ETV4. The neoplastic cells expressed differentiation markers such as Nkx3.1 recapitulating luminal gene expression features of untreated human prostate cancer. Single-cell and bulk RNA sequencing showed that stabilized ETV4 induced a previously unidentified luminal-derived expression cluster with signatures of cell cycle, senescence, and epithelial-to-mesenchymal transition. These data suggest that ETS overexpression alone, at sufficient dosage, can initiate prostate neoplasia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Sandra and Edward Meyer Cancer Center and Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY 10065, USA.
- Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY 10065, USA.
- Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
ORCID-Profile: Dan Li, Yu Zhan, Naitao Wang, Fanying Tang, Gabriella Bayshtok, Amanda R Moore, Jessica Sher, Jimmy L Zhao, Joseph Chan, Ekta Khurana, Nora M Navone, Ping Chi, Yu Chen
Förderung
- NCI NIH HHS
Zitieren
APA
Li, D., Zhan, Y., Wang, N., Tang, F., Lee, C. J., Bayshtok, G., Moore, A. R., Wong, E. W. P., Pachai, M. R., Xie, Y., Sher, J., Zhao, J. L., Khudoynazarova, M., Gopalan, A., Chan, J., Khurana, E., Shepherd, P., Navone, N. M., Chi, P., & Chen, Y. (2023). ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer. Science Advances, 9(14). https://doi.org/10.1126/sciadv.adc9446
Vancouver
Li D, Zhan Y, Wang N, Tang F, Lee CJ, Bayshtok G, et al. ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer. Science Advances. 2023;9(14). doi:10.1126/sciadv.adc9446
BibTeX
@article{Li2023,
author = {Li, Dan and Zhan, Yu and Wang, Naitao and Tang, Fanying and Lee, Cindy J and Bayshtok, Gabriella and Moore, Amanda R and Wong, Elissa W P and Pachai, Mohini R and Xie, Yuanyuan and Sher, Jessica and Zhao, Jimmy L and Khudoynazarova, Makhzuna and Gopalan, Anuradha and Chan, Joseph and Khurana, Ekta and Shepherd, Peter and Navone, Nora M and Chi, Ping and Chen, Yu},
title = {ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer},
journal = {Science Advances},
year = {2023},
volume = {9},
number = {14},
doi = {10.1126/sciadv.adc9446}
}
EUVIMED